-
公开(公告)号:BG107165A
公开(公告)日:2003-07-31
申请号:BG10716502
申请日:2002-10-03
Applicant: ABBOTT LAB
Inventor: DICKMAN DANIEL A , CHEMBURKAR SANJAY , FORT JAMES J , HENRY RODGER F , LECHUGA-BALLESTEROS DAVID , NIU YUPING , PORTER WILLIAM
IPC: A61K20060101 , A61K31/513 , A61P20060101 , A61P31/18 , A61P43/00 , C07D20060101 , C07D239/10
Abstract: The invention relates to new crystalline forms of lopinavir with peaks in the solid phase infrared spectrum in the interval 1652-1666 cm-1 and 1606-1615 cm-1, and to methods for their preparation. The crystalline forms are used for the purification or isolation of lopinavir or for the production of pharmaceutical preparations. 23 claims, 31 figures
-
公开(公告)号:NO20024679L
公开(公告)日:2002-09-30
申请号:NO20024679
申请日:2002-09-30
Applicant: ABBOTT LAB
Inventor: DICKMAN DANIEL A , CHEMBURKAR SANJAY , FORT JAMES J , HENRY RODGER F , LECHUGA-BALLESTEROS DAVID , NIU YUPING , PORTER WILLIAM
IPC: A61K20060101 , A61K31/513 , A61P20060101 , A61P31/18 , A61P43/00 , C07D20060101 , C07D239/10
Abstract: New crystalline forms of lopinavir are disclosed.
-
公开(公告)号:ES2642054T3
公开(公告)日:2017-11-15
申请号:ES14187517
申请日:2006-12-12
Applicant: ABBOTT LAB
Inventor: DHAON MADHUP , HSIAO CHU-NUNG , PATEL SUBHASH , BONK PETER , CHEMBURKAR SANJAY , CHEN YONG
IPC: C07D498/18 , A61K31/395
-
公开(公告)号:AU2014200017B2
公开(公告)日:2016-06-09
申请号:AU2014200017
申请日:2014-01-03
Applicant: ABBOTT LAB
Inventor: HSIAO CHU-NUNG , DHAON MADHUP , CHEN YOUNG , CHEMBURKAR SANJAY , PATEL SUBHASH , BONK PETER
IPC: C07D498/18 , A61K31/395
Abstract: ONE POT SYNTHESIS OF TETRAZOLE DERIVATIVES OF SIROLIMUS A single-step, one-pot process to obtain zotarolimus and other rapamycin derivatives on large scale that improves currently available syntheses. In one embodiment, dried rapamycin is dissolved in isopropylacetate. After cooling and 2,6-Lutidine addition, triflic anhydride is slowly added at -30'C. Salts are removed by filtration. Tetrazole, followed by a tert-base diisopropylethylamine is added. After incubation at room temperature, the product is concentrated and purified by a silica gel column using THF/heptane as eluant. The product is collected, concentrated, and purified using an acetone/heptane column. The product-containing fractions are concentrated. The product is dissolved in t-BME and precipitated with heptane. The solids are dissolved in acetone, treated with butylated-hydroxy toluene, and the solution concentrated. The process is repeated twice with acetone to remove solvents. At least one stabilizing agent is added, such as BHT at 0.5% before drying.
-
公开(公告)号:AU2014200017A1
公开(公告)日:2014-01-23
申请号:AU2014200017
申请日:2014-01-03
Applicant: ABBOTT LAB
Inventor: HSIAO CHU-NUNG , DHAON MADHUP , CHEN YOUNG , CHEMBURKAR SANJAY , PATEL SUBHASH , BONK PETER
IPC: C07D498/18 , A61K31/395
Abstract: ONE POT SYNTHESIS OF TETRAZOLE DERIVATIVES OF SIROLIMUS A single-step, one-pot process to obtain zotarolimus and other rapamycin derivatives on large scale that improves currently available syntheses. In one embodiment, dried rapamycin is dissolved in isopropylacetate. After cooling and 2,6-Lutidine addition, triflic anhydride is slowly added at -30'C. Salts are removed by filtration. Tetrazole, followed by a tert-base diisopropylethylamine is added. After incubation at room temperature, the product is concentrated and purified by a silica gel column using THF/heptane as eluant. The product is collected, concentrated, and purified using an acetone/heptane column. The product-containing fractions are concentrated. The product is dissolved in t-BME and precipitated with heptane. The solids are dissolved in acetone, treated with butylated-hydroxy toluene, and the solution concentrated. The process is repeated twice with acetone to remove solvents. At least one stabilizing agent is added, such as BHT at 0.5% before drying.
-
公开(公告)号:BG110080A
公开(公告)日:2008-11-28
申请号:BG11008006
申请日:2006-09-20
Applicant: ABBOTT LAB
Inventor: BAUER JOHN , SALEKI-GERHARDT AZITA , NARAYANAN BIKSHANDARKOIL , CHEMBURKAR SANJAY , PATEL KETAN , SPIWEK HARRY , BAUER PHILIP , ALLEN KIMBERLY
IPC: C07D277/24 , A61K31/425 , A61K31/426 , A61K31/427 , A61P31/18 , A61P37/04 , C07D277/28 , C07D277/30 , C07D277/36 , C07D277/40 , C07D277/42 , C07D417/12
Abstract: The invention relates to (2S, 3S, 5S)-5-{N-(/N-methyl-N-[/2-isopropyl-4-thiasolyl/methyl]amino/carbonyl-L-valinyl)amino]-2-{N-[/5- thiazolyl/methoxycarbonyl]amino}-1,6-diphenyl-3-hydroxyhexan} (ritonavir), in particular to essentially pure crystalline ritonavir, to methods for obtaining it, and to pharmaceutical compositions containing it. The invention relates also to a method for obtaining an essentially pure crystalline polymorphous form II of ritonavir.
-
公开(公告)号:CA2997700A1
公开(公告)日:2007-08-23
申请号:CA2997700
申请日:2006-12-12
Applicant: ABBOTT LAB
Inventor: DHAON MADHUP , HSIAO CHI-NUNG , PATEL SUBHASH , BONK PETER , CHEMBURKAR SANJAY , CHEN YONG
IPC: C07D498/18
Abstract: A single-step, one-pot process to obtain zotarolimus and other rapamycin derivatives on large scale that improves currently available syntheses. In one embodiment, dried rapamycin is dissolved in isopropylacetate. After cooling and 2,6-Lutidine addition, triflic anhydride is slowly added at -30°C. Salts are removed by filtration. Tetrazole, followed by a tert-base diisopropylethylamine is added. After incubation at room temperature, the product is concentrated and purified by a silica gel column using THF/heptane as eluant. The product is collected, concentrated, and purified using an acetone/heptane column. The product-containing fractions are concentrated. The product is dissolved in t-BME and precipitated with heptane. The solids are dissolved in acetone, treated with butylated-hydroxy toluene, and the solution concentrated. The process is repeated twice with acetone to remove solvents. At least one stabilizing agent is added, such as BHT at 0.5% before drying.
-
公开(公告)号:CA2631971A1
公开(公告)日:2007-08-23
申请号:CA2631971
申请日:2006-12-12
Applicant: ABBOTT LAB
Inventor: PATEL SUBHASH , HSIAO CHU-NUNG , DHAON MADHUP , CHEMBURKAR SANJAY , BONK PETER , CHEN YONG
IPC: C07D498/18 , A61K31/395
Abstract: A single-step, one-pot process to obtain zotarolimus and other rapamycin derivatives on large scale that improves currently available syntheses. In o ne embodiment, dried rapamycin is dissolved in isopropylacetate . After cooling and 2,6-Lutidine addition, triflic anhydride is slowly added at -30~ C. Salt s are removed by filtration. Tetrazole, followed by a tert-base diisopropylethylamine is added. After incubation at room temperature, the product is concentrated and purified by a silica gel column using THF/heptan e as eluant. The product is collected, concentrated, and purified using an acetone/heptane column. The product-containing fractions are concentrated. T he product is dissolved in t-BME and precipitated with heptane. The solids are dissolved in acetone, treated with butylated-hydroxy toluene, and the soluti on concentrated. The process is repeated twice with acetone to remove solvents. At least one stabilizing agent is added, such as BHT at 0.5% before drying.
-
公开(公告)号:AU2006338175A1
公开(公告)日:2007-08-23
申请号:AU2006338175
申请日:2006-12-12
Applicant: ABBOTT LAB
Inventor: HSIAO CHU-NUNG , CHEN YOUNG , BONK PETER , CHEMBURKAR SANJAY , DHAON MADHUP , PATEL SUBHASH
IPC: C07D498/18 , A61K31/395
Abstract: A single-step, one-pot process to obtain zotarolimus and other rapamycin derivatives on large scale that improves currently available syntheses. In one embodiment, dried rapamycin is dissolved in isopropylacetate. After cooling and 2,6-Lutidine addition, triflic anhydride is slowly added at -30°C. Salts are removed by filtration. Tetrazole, followed by a tert-base diisopropylethylamine is added. After incubation at room temperature, the product is concentrated and purified by a silica gel column using THF/heptane as eluant. The product is collected, concentrated, and purified using an acetone/heptane column. The product-containing fractions are concentrated. The product is dissolved in t-BME and precipitated with heptane. The solids are dissolved in acetone, treated with butylated-hydroxy toluene, and the solution concentrated. The process is repeated twice with acetone to remove solvents. At least one stabilizing agent is added, such as BHT at 0.5% before drying.
-
公开(公告)号:BG109682A
公开(公告)日:2007-03-30
申请号:BG10968206
申请日:2006-09-20
Applicant: ABBOTT LAB
Inventor: BAUER JOHN , SALEKI-GERHARDT AZITA , NARAYANAN BIKSHANDARKOIL , CHEMBURKAR SANJAY , PATEL KETAN , SPIWEK HARRY , BAUER PHILIP , ALLEN KIMBERLY
IPC: C07D277/24 , A61K31/425 , A61K31/426 , A61K31/427 , A61P31/18 , A61P37/04 , C07D277/00 , C07D277/28 , C07D277/30 , C07D277/36 , C07D277/40 , C07D277/42 , C07D417/12
Abstract: The invention relates to (2S,3S,5S)-5-{N-[N-(/N-methyl-N-[/2-isopropyl-4-thiazolyl/methyl]amino}carbonyl-L-valinyl)amino]-2-{N-[/5- thiazolyl/methoxycarbonyl]amino}-1,6-diphenyl-3-hydroxyhexane} (ritonavir), in particular to essentially pure amorphous ritonavir, to methods of obtaining it, to pharmaceutical compositions containing it, as well as to a method of obtaining essentially pure crystalline polymorphous forms I and II of ritonavir.
-
-
-
-
-
-
-
-
-